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Abstract
Objective: There are controversies regarding the pro-angiogenic activity of placental growth factor (PGF) in diabetic
retinopathy (DR). For a better understanding of its role on the retina, we have evaluated the effect of a sustained PGF over-
expression in rat ocular media, using ciliary muscle electrotransfer (ET) of a plasmid encoding rat PGF-1 (pVAX2-rPGF-1).
Materials and Methods: pVAX2-rPGF-1 ET in the ciliary muscle (200 V/cm) was achieved in non diabetic and diabetic rat
eyes. Control eyes received saline or naked plasmid ET. Clinical follow up was carried out over three months using slit lamp
examination and fluorescein angiography. After the control of rPGF-1 expression, PGF-induced effects on retinal vasculature
and on the blood-external barrier were evaluated respectively by lectin and occludin staining on flat-mounts. Ocular
structures were visualized through histological analysis.
Results: After fifteen days of rPGF-1 over-expression in normal eyes, tortuous and dilated capillaries were observed. At one
month, microaneurysms and moderate vascular sprouts were detected in mid retinal periphery in vivo and on retinal flat-
mounts. At later stages, retinal pigmented epithelial cells demonstrated morphological abnormalities and junction ruptures.
In diabetic retinas, PGF expression rose between 2 and 5 months, and, one month after ET, rPGF-1 over-expression induced
glial activation and proliferation.
Conclusion: This is the first demonstration that sustained intraocular PGF production induces vascular and retinal changes
similar to those observed in the early stages of diabetic retinopathy. PGF and its receptor Flt-1 may therefore be looked
upon as a potential regulatory target at this stage of the disease.
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Introduction
Pathogenic events in diabetic retinopathy (DR) include capillary
basement membrane thickening, loss of microvascular intramural
pericytes and leaky dilation [1–2]. At more advanced stages,
capillary occlusion induces retinal ischemia and subsequent
retinovitreal neovascularization causing bleeding and traction
retinal detachments. Since its discovery in ocular fluids from
patients with proliferative diabetic retinopathy (PDR) [3–4],
VEGF has been recognized as a major pro angiogenic factor
produced in response to hyperglycaemia and ischemia. Even
though few animal models reproduce one or more of the DR
lesions with unquestionable validity, non-diabetic animal models
have been exploited to study retinal neovascularization pathogen-
esis [5]. The retinopathy of prematurity model is commonly used
to study ischemic-related retinal diseases [6–7]. The angiogenic
effects of VEGF have also been analyzed in transgenic mice
models of ocular neovascularizations [8–9] or using viral VEGF
gene transfer [10–11]. Whilst VEGF blockade has been demon-
strated to efficiently reduce neovascularization progression and
leakage in age-related macular degeneration, its exact place in the
management of DR remains to be clarified. Intravitreal anti-
VEGFs do improve vitrectomy outcome in cases of severe PDR
[12] but should be administered shortly before surgery to avoid
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traction retinal detachments [13–14], and may potentially
aggravate retinal ischemia. The effectiveness of anti VEGF
therapies in patients with diabetic macular edema remains
disputable [15] and suggests that other hypoxia-induced molecular
factors may be involved such as PDGF, IGF-1, HGF, bFGF/FGF-
2 [16]. Among them, placental growth factor (PGF) found at high
levels in the vitreous [17–19] and the retina [20] of diabetic
patients may have particular interest.
PGF is a homologue of VEGF [21] which binds to Flt-1 and to
the co-receptors neuropilin21 and 22, but does not bind to Flk-1
[22]. During vascular development, PGF is redundant with VEGF
but, in pathological conditions, it acts directly on Flt-1-mediated
endothelial migration and vascular permeabilization, and indi-
rectly on Flk-1-mediated angiogenesis [23]. Whilst PGF chemo-
tactic and angiogenic properties were highlighted early in the
rabbit cornea [24], its implication in angiogenic diseases has been
controversial. When over-expressed in VEGF-producing cells,
VEGF/PGF heterodimers induced either inhibition [25–26] or
enhancement [22,27] of the VEGF pro angiogenic effects by
interfering with Flk-1 binding. Similarly, the effect of hypoxia on
PGF expression appeared to be cell-dependent [27–31]. In the
retina, all the members of the VEGF family are expressed,
primarily in ganglion cells, and up-regulated during ischemia.
Moreover, we have previously shown that, under hypoxic
conditions, RPE cells express PGF-1 and its receptor Flt-1 [19].
Over the last decade, the direct or indirect pro angiogenic effect
of PGF was demonstrated during ischemia, inflammation, wound
healing and cancer [32–34], as well as in skin angiogenesis [35]. In
the eye, loss of PGF does not hamper retinal development [36] but
impairs choroidal neovascularization [37], as does the loss of Flt-1
[38]. Intravitreal injections of PGF prevent oxygen-induced retinal
ischemia, without inducing neovascularization [39]. Acute injec-
tion of PGF in the rat vitreous also altered the outer retinal barrier
[19]. Taken together, these results tend to show that PGF may be
involved in retinal pathology, but the effects of a sustained over-
expression of PGF have not been studied.
We have recently developed a new non-viral method for gene
transfer, based on electrotransfer (ET), using the ciliary muscle as a
local bio-factory for the production secreted proteins [40–44]. In
the present study, we used this method to characterize clinical and
histo-pathological ocular changes induced by sustained secretion
of rat PGF-1 (rPGF-1) in the rat eye in vivo.
Methods
Animals and fibrovascular membranes
Investigations were performed in accordance of the ARVO
statement for the Use of Animals in Ophthalmic Vision Research.
The study was approved by the Regional Ethics Committee in
Animal Experiment Nu3 of Ile-de-France region (approval p3/
2008/062). Eighteen non-dystrophic Royal College of Surgeon’s
(cRCS: RCS- rdy+/p2) rats aged two months, from our facility,
were first used as non pigmented and non-diabetic model to follow
up the effects of PGF over expression. Due to the difficulty to
observe albino eye fundi by fluorescein angiography (FA), Brown-
Norway (BN) rats were then chosen as pigmented model, and
purchased from Charles-River (L’Arbresle, France; N=15) or from
Janvier (Le Genest Saint Isle, France; N=5). Eleven Goto-Kakizaki
(GK) male rats, a model of non obese type 2 diabetes and three non-
diabetic GK female rats from our facility were used to study PGF
expression in diabetic conditions. All experiments were performed
under ketamine/chlorpromazine (80 mg/kg/0.5 mg/kg) anesthe-
sia. During clinical follow up, 1% tropicamide was used to dilate
pupils. Animals were sacrificed by carbon dioxide inhalation.
Two fibrovascular pre-retinal membranes were obtained from
eyes with PDR during closed microsurgery at the Lariboisie`re
Hospital. Membranes were kept at 280uC immediately following
removal, until Tissue-TekH OCT (Sakura Finetek Europe,
Zoeterwoude, Netherlands) embedding.
Plasmids and ciliary muscle electrotransfer
The pVAX2-rPGF-1 plasmid is a 3.4 kb vector encoding rPGF-1
which was constructed after isolation, reverse transcription and
amplification of rPGF-1 mRNA from rat placenta in order to limit
the effect of immune response. After injection of 30 mg of plasmid
(in 10 mL in saline) in the ciliary muscle using the trans-scleral route,
electrotransfer was performed as previously described (40–43).
Control eyes received ET of saline or ET of naked pVAX2 plasmid.
Because no significant differences were observed between the
groups of rats treated with ET of either saline or the naked plasmid,
we have only represented the group of rats treated with ET of saline
for more clarity in the different graphs.
Clinical follow up and experimental design
Non-pigmented rats were firstly separated into two groups: a
control groups (saline ET, N=6, pVAX2 ET, N=6) and a
‘‘treated’’ group (pVAX2-rPGF-1 ET, N=6). The eye fundi were
observed by slit lamp examination at days 4, 14 and 30 after ET.
At this time point, one half of the rats were sacrificed for further
analysis, and the other half was kept until day 100 for histological
analysis. Controls (N= 10) and treated (N=5) pigmented BN rats
were examined by FA at weeks 4 and 6 after ET. For this purpose,
fluorescein (0.2 mL of 10% fluorescein in saline) was administrated
intraperitoneally. Angiograms were established using the Pro-3
Fundus Camera (Kowa) and saved on the Lhediaph LK3 software
(L’Heritier). At two months, rPGF-1 expression was controlled by
RT PCR and immuno-histochemical analyses were performed.
Five more BN rats (N= 3 treated + 2 control) were follow up,
between weeks 2 and 5 after ET, with a confocal scanning laser
ophthalmoscope (cSLO) (HRA, Heidelberg Engineering, Dossen-
heim, Germany) [45]. The following grading system was used to
quantify vascular changes as observed on angiography: Grade 0,
normal retinal vasculature; +1 point for each of the following
changes: dilated or tortuous vessels, microaneurysmal-like hyper-
fluorescent dots ,10 or hyperfluorescence around the optic nerve
head; +2 points for microaneurysmal-like hyperfluorescent dots
.10.
Finally, GK rats (N= 4 treated + 4 control) were analyzed by
immuno-histochemistry, one month after ET. Blood sugar level
were measured with the Accu-Check activeH system (Roche
Diagnostics, Meylan, France).
Polymerase Chain Reactions (PCR)
After dissection under an operating microscope, ‘‘ciliary
muscle/bodies- iris’’ complexes and retinal tissues were removed
and kept at 280uC until use. For each sample, total mRNA was
isolated using the RNeasy plus mini kit (Qiagen, Courtaboeuf,
France) following the manufacturer’s instructions. One mg of total
RNA was readjusted according to the RNA optic density at
260 nm, and then single-stranded cDNA was synthesized using
random primer and superscript reverse transcriptase (Invitrogen,
Cergy Pontoise, France).
Reverse Transcription PCR. cDNA from ‘‘Ciliary muscle/
bodies- iris’’ complexes were amplified with rPGF-1 (sense, 59-
ATG CTG GCC ATG AAG CTG TTC-39; antisense, 59-ACT
GAG GAA CCC CAC CTG TGA-39), rat VEGF-A165 (sense, 59-
TTCATGGATGTCTATCAGCG-39; antisens, 59-GCTCATC-
TCTCCTATGTGCT-39) and GAPDH (sense, 59-ATG CCC
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CCA TGT TTG TGA TG-39; antisense, 59-ATG GCA TGG
ACT GTG GTC AT-39)-specific primers. These primers were
designed to amplify cDNA fragments of 477 bp for rPGF-1,
234 bp for VEGF and 162 bp for GAPDH. For rPGF-1 and
GFAP amplifications, thirty cycles of three PCR steps made of 1
minute at 94uC, 2 min at 56uC and 3 min at 72uC were
performed. For VEGF amplification, after one step at 94uC,
2 min, forty cycles of 30 sec at 94uC, 1 min at 55uC and 1 min at
72uC were performed. PCR fragments were analyzed by 2.5%
agarose gel electrophoresis and visualized by ethidium bromide
staining under UV. The relative band intensities for both growth
factors were calculated in comparison with that for GAPDH.
Real-Time PCR. For retinal extracts, reverse transcription
was followed by real time PCR using 5 ml cDNA, TaqManH
Universal PCR Master Mix, No AmpEraseH UNG for the
following primers (Applied Biosystems CA, USA): 18S (Hs99999-
901_s1); TNF-alpha (Rn01525860_g1); IL-1beta (Rn00676333_
g1); IL-6 (Rn01410330_m1); VEGF-A (Rn01511608_m1). The
reactions were performed on 7300 Real-Time PCR System
(Applied Biosystems CA, USA) in 40 cycles of 15 sec at 95uC,
1 min at 60uC. Product was not generated in control reactions in
which cDNA were omitted during synthesis. Relative
quantification of real-time PCR results was performed by using
the ‘‘delta-delta Ct method’’.
Flat-mounts of neuroretinas and of the remaining
RPE-choroid-sclera complexes
After fixation of whole eyes, 15 min in paraformaldehyde (PAF)
4% solution in saline, anterior segments were discarded and the
neuroretinas were carefully separated. Post-fixation was carried
out for 10 min at 220uC in methanol for retinas and in acetone
for RPE-choroid-sclera complexes. After rehydratation with PBS
Triton X 100 1% solution, neural retinas were incubated
overnight with the FITC-conjugated lectin from Bandeiraea
simplicifolia (1:100; Sigma-Aldrich, St-Quentin Fallavier, France)
and, RPE-choroid-sclera complexes, with a polyclonal rabbit anti-
occludin antibody (1:400; Invitrogen). Occludin was visualized by
incubation with an Alexa-594-conjugated goat anti rabbit IgG
(1:200; Invitrogen). After washing, tissues were flat-mounted in gel
mount (Biomeda Corp., Foster City, CA, USA) and examined
with a fluorescence microscope Olympus BX51 (Rungis, France)
coupled with a digital camera Olympus DP70, or with a confocal
microscope Zeiss LSM 710 (Le Pecq, France).
Histological analysis
Eyes were fixed in PAF 4% and glutaraldehyde 0.5% solution in
saline for 2 hours, dehydrated and embedded in historesin (Leica
Microsystems, Nussloch GmbH, Germany). Sections of 5 mm were
stained with 0.5% toluidine blue (Serva, Paris, France) and
observed with an Aristoplan microscope (Leitz) coupled with a
Leica DFC480 camera.
Immunohistochemistry
Dual immuno-staining were performed on 10-mm cryostat
sections from non-pigmented eyes and diabetic human fibrovas-
cular membranes, fixed 5 min in PAF 4% solution. The sections
were incubated one hour at room temperature with a polyclonal
goat antibody raised against rPGF-1 (1:100, #sc-1883, Santa-
Cruz Biotechnology, CA, USA), associated with a monoclonal
mouse anti-alpha smooth muscle actin (alpha-SMA) antibody
(1:100; Chemicon International/Millipore, Molshein, France), or a
polyclonal rabbit anti-glial fibrillary acidic protein (GFAP)
antibody (1:100; Dako Cytomation, Trappes, France), or a
polyclonal rabbit von Willebrand factor (vW) antibody (1/100;
Dako Cytomation). The secondary antibodies used (1:250;
Invitrogen) included an Alexa-488-conjugated rabbit anti-goat
antibody, a Texas-Red-conjugated donkey anti-mouse antibody,
and a donkey Alexa-594 conjugated anti-rabbit antibody.
Controls involved the omission of the primary antibody. The
sections were stained 5 min with 49, 6 diamidino-2-phenylindole
solution (DAPI, 1:5000; Sigma-Aldrich, Saint-Quentin Fallavier,
France), mounted in glycerol:PBS (1:1), and viewed with the
fluorescence microscope.
Western-blot
As only male GK rats become diabetic with ageing, PGF
immuno-blotting was performed on protein extracted from the
entire retinas of three diabetic male rats - aged two, five and twelve
months, and compared to PGF expression the neuroretina from
three non diabetic GK female rats - aged one, five and twelve
months. Neuroretinas were homogenized in lysis buffer (10 mM
Tris-HCl PH 7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl,
0.5% Nonidet P40, 1% Triton X-100, b-mercaptoethanol)
containing protease inhibitor cocktail (Roche). Forty mg of proteins
were subjected to SDS-PAGE in a NuPageH 4–12% polyacryl-
amide gel (Invitrogen) and electroblotted onto a nitrocellulose
membrane (Schleicher &Schuell BioScience, Dassel, Germany).
The membrane was incubated with the anti-rPGF-1 antibody
(1:1000) over-night at 4uC, and then, incubated with a
corresponding secondary antibodies, horseradish peroxidase-
conjugated Fab fragment (1:5000; Caltag, Burlingame, Canada),
one hour at room temperature. Immuno-reactive bands were
detected with the ECL Western Blotting Detection Reagents Kit
(Amersham Biosciences, Orsay, France). To check for equal
loading, membranes were probed with an anti-beta-tubulin
antibody (Serotec, Du¨sseldorf, Germany).
Statistics
PCR results and histological measurements were expressed as
the mean6SEM. The Mann-Whitney U-test was used to
determine differences between groups. A P value ,0.05 was
considered statistically significant.
Results
Effect the sustained over expression of r PGF-1 in non
diabetic rat eye
rPGF over-expression was controlled at two months
after ET. PCR products from the circumferential ciliary region
revealed an expected 477 bp rPGF-1 band in both the treated and
control group, and showed that rPGF-1, but not VEGF, was
significantly increased in pVAX2-rPGF-1 ET-treated eyes as
compared to saline ET-treated eyes (p = 0.008) (Fig. 1a). Immuno-
staining revealed rPGF-1 localization in the ciliary muscle and in
the ciliary body epithelium (Fig. 1b).
The over-expression of rPGF-1-induced retinal vessels
changes. In vivo. At day 4, using indirect ophthalmoscopy on
albinos rats, no difference between pVAX2-rPGF-1 ET-treated
and control eyes were observed. At day 14 and 30, respectively one
third (n = 4/12 eyes) and one half (n = 6/12) of the treated eyes
presented tortuous vessels and microvascular abnormalities. At
day 100, focal regions of sub retinal fluid accumulation were
observed in half of the rPGF-1-treated eyes (n = 3/6), demons-
trating progressive vessel abnormalization upon sustained PGF1
exposure.
Fluorescein angiography (FA) on pigmented eyes and the
definition of a grading system (Fig. 2a) allowed a more precise
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analysis of the PGF-induced effects on retinal vasculature. Control
rats showed normal vasculature throughout the follow-up period
(Fig. 2a, Grade 0). Four weeks after ET, 40% of the PGF-treated
eyes (n = 4/10) demonstrated dilated (mostly veins) and tortuous
(mostly arterial) vessels, in central and peripheral retina (Fig. 2a,
Grade 2). Six weeks after ET, 60% (n= 6/10) showed focal vessel
leakage in the mid retinal periphery (Fig. 2a, Grade 3/4). Hyper
fluorescent dots appeared as leaky micro-aneurysms. In three eyes,
profuse dye leakage around the ONH increased with the
angiographic sequence time, signing large vessel permeabilization
(Fig. 2a, +1 point). No clear retinal neovascularization was
observed at this time point.
The cSLO made it possible to carry out an accurate follow up of
six more eyes in which rPGF-1 was overexpressed, compared to
normal eyes (Fig. 2b, Grade 0). At week 3, their angiograms
demonstrated vasodilation and vascular tortuosity (n = 4/6; Fig. 2b,
Grade 2), and microaneurysms on capillaries (n = 2/6; Fig. 2b,
Grade 3). At week 5, these four eyes presented more hyper-
fluorescent dots on capillaries than earlier, along with focal
neovascular sprouting (Fig. 2b, +1 point).
Ex vivo. Analysis of the flat-mounted retinas at low
magnification (Fig. 3a) demonstrated that the lectin-labeled
vascularized area was significantly increased in the rPGF-1
treated group as compared to the control group (23.7%61.1%
vs 18.8%60.5%, p= 0.0034), particularly in the mid periphery
(Fig. 3b), an area showing numerous tortuous capillaries (Fig. 3c).
Whereas some areas appeared unperfused on FA (Fig. 4a),
magnified confocal imaging allowed to observe a strong superficial
cellular infiltration leading to a vascular sprout lay in the lower
capillary bed. Infiltrating cells were also observed around and in
the superficial vicinity of the vascular knots appearing as hyper-
fluorescent dots on FA (Fig. 4b). In the mid retinal periphery,
others protrusions and vascular irregularities were identified
(Fig. 4c–d). Two months after ET, intra-retinal vascular
abnormalities (Fig. 4e): vascular loop, sprouting of endothelial
cells and microaneurysms, were also observed.
At this time point, the expression of angiogenic and inflamma-
tory mediators was evaluated at the mRNA level in the
neuroretina (Fig. 4f). As compared to control eyes, rPGF-1 over-
expression induced significant up regulation of IL-6 (more than 10
times increase) and VEGF, and down-regulation of IL-1beta and
TNF-alpha.
rPGF-1-induced effects on retinal histology. Three
months after pVAX2-rPGF-1 ET, historesin sections showed
vascular abnormalities at the vitreoretinal interface, including focal
vessel dilation (Fig. 5a2) and pre retinal vascular sprouting
(Fig. 5a3–4). In the retina, focal detachments were observed in
regions in which RPE cells were abnormal (Figure 5b3–b4), that is
in favor of fluid accumulation in the sub retinal space. Changes in
the morphology of RPE cells could be observed both on sections
(Fig. 5b4) and on flat-mounted RPE (Fig. 5c2). These preparations
also demonstrated focal disruptions of the tight-junctions, as shown
by occludin staining, and the presence of infiltrating cells with
small nuclei on the apical side of RPE cells (Fig. 5c4) which were
not found in control eyes (Fig. 5c3).
Endogenous expression of PGF in the time course of
diabetic retinopathy in GK rats
Before over-expressing PGF in diabetic GK rats, we have
evaluated whether the endogenous expression of PGF was
modified in the retina of GK rats after different time of
hyperglycemia.
In non-diabetic untreated eyes, PGF immuno-localization
showed that PGF-1 is expressed in retinal Mu¨ller glial (RMG)
cells and in the inner segments of photoreceptors (Fig. 6a). In
three-month-old GK diabetic rats, PGF-1 was strongly expressed
in the inner part the retina, mostly in astrocytes and in swollen
RMG cells, as shown by the co labeling with the glial marker,
GFAP (Fig. 6b). PGF expression over time in diabetic retinas was
compared to PGF expression in control retinas using western-blot
(Fig. 6c). This kinetic showed that PGF expression increased in
the neuroretinas from diabetic rats aged between two and five
Figure 1. Control of rPGF-1 expression. (a) PGF and VEGF expression analysis at the mRNA level, two months after pVAX2-rPGF ET.
Mean relative band intensity 6SEM determined after detection of rPGF-1, rVEGF and GAPDH mRNA expression in control eyes (in white, n = 5) or in
pVAX2-rPGF-1 ET treated eyes (in black, n = 5); **, p = 0.0079. Representative RT-PCR products visualized by ethidium bromide staining are shown. (b)
Localization of rPGF-1 expression on sections of the ciliary muscle, one month after saline ET (Control) or pVAX2-rPGF ET (PGF ET).
Alpha-smooth muscle actin (aSMA) - Texas-Red labeling allows localization of the ciliary muscle (cm). Compared to control eye, white arrowheads
indicate that after pVAX2-rPGF-1 ET, the protein of interest which is labeled in green, is localized in muscle fibers and in the epithelium of ciliary
bodies (cb). No staining was observed when the primary antibody was omitted. Scale bars: 100 mm.
doi:10.1371/journal.pone.0017462.g001
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months, and remained elevated as the diabetes develops at later
stages (12 months), whereas it remained constant between one
month and one year in retinas from non diabetic control rats.
PGF-1 is therefore upregulated in the retina of GK diabetic rats,
increasing at the early stages of diabetes and remaining elevated
thereafter.
In addition, analysis of the lectin-labeled flat-mounts, retinas
from 5 months-old GK eyes demonstrated some vascular
abnormalities. In normal GK retinas, vascularized area was
higher (27.2%60.03%) than in normal non diabetic retinas
(18.8%60.02%, p,0.0001%), and vessels appeared tortuous with
some vascular irregularities (Fig. 7b1–b3).
Figure 2. Fluorescein angiograms of Brown-Norway rat eyes. (a) Observations with a classic angiograph (Pro III Fundus camera,
Kowa), 4 and 6 weeks after pVAX2-rPGF ET. Angiograms were established with a scan angle of 30u. Vascular abnormalities were scored from 0
to 5 in accordance to the following grading: Grade 0, normal retinal vasculature, as observed in control fundus at week 6 (ONH, Optic Nerve Head);
+1 point for each of the following changes - dilated (between white arrowheads) or tortuous (white arrows) vessels, microaneurysmal-like
hyperfluorescent dots (black arrowheads) ,10 or hyper-fluorescence around the ONH; +2 points for microaneurysmal-like hyper-fluorescent dots
.10. (b) Observations with a confocal scanning Laser Ophthalmoscope (cSLO, Heidelberg Retina Angiograph I), 2, 3 and 5 weeks
after pVAX2-rPGF ET. The same grading was used to score vascular abnormalities. The higher resolution of the cSLO allowed the observation of
early fluorescein leakage (Grade 1), and the detection of strong vascular abnormalities at later stage (+ 1 point).
doi:10.1371/journal.pone.0017462.g002
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Effect of the sustained over expression of rPGF-1 in GK
diabetic rat eyes
rPGF-1 over-expression in GK rats did not enhance or modify
the vessel abnormalities observed in the control GK rats treated
with either ET of saline or ET of naked plasmid. The vascularized
areas were not statistically different in GK control rats and PGF-
treated GK rats (Fig. 7a). Magnified observations highlighted
cellular infiltration in diabetic retinas which seemed enhanced by
rPGF-1 over expression (Fig. 7b4).
However, rPGF-1 induced intense glial activation. Indeed,
strong GFAP staining was found in the retina from rPGF-1-treated
eyes as compared to control diabetic retina and ET saline control
diabetic retina (not shown). Indeed, we have previously shown that
ET of ciliary muscle does not induce activation of inflammation
markers because it does not imply perforation of the retina and the
Figure 3. Morphological analysis of flat-mounted retina labeled with FITC-conjugated lectin from Bandeira simplicifolia. (a)
Illustration of the procedure followed with ‘‘ImageJ’’ software. (a1) Selection of seven areas per group, in mid (700x500 px) and extreme
(400x300 px) peripheries on mosaics (3007x2904 px) made with microscopic images at low magnification (x4). (a2) Application of steerable filters for
ridge detection in the selected image, with the plug-in ‘‘Feature Detector’’ [57]. (a3) Transformation of the filtered image into a binary image allowing
selection of the retinal vessels to calculate the vascularized area (area covered by vessels out of total area, Av/At). (a4) Derivation of the vascular
skeleton from the binary image, using the procedure ‘‘skeletonizes’’. This second binary picture was used to calculate the tortuosity index
corresponding to the ratio: real vessel length (L2, in red) out of the length of an imaginary straight line on the measured vessel (L1, in blue) as shown
in d1 and d2. (b–c) Quantitative analysis of the retinal vasculature from control (CTL) and PGF ET-treated eyes. (b) Vascularized area
calculated from the binary images which are illustrated in c1 and c2. All data: CTL, 18.8%60.5%; PGF-ET, 23.7%61.1%; ** p = 0.0034.Mid periphery:
CTL, 19.4%60.7%; PGF-ET, treated eyes 25.1%60.8%; Bonferroni, ** p,0.01. Extreme periphery: CTL, 18.2%60.7%; PGF-ET treated eyes
21.2%61.7%; Bonferroni, ns. (c) Tortuosity index of capillaries calculated from the second binary images. CTL, controls 1.05360.005; PGF-ET, treated
eyes 1.18060.014; *** p,0.0001; PGF ET/CTL= 1.12.
doi:10.1371/journal.pone.0017462.g003
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treatment area is anterior. rPGF-1 was mostly located in RMG
cells, but it was also found in RPE cells and in large cells infiltrating
the sub retinal space (Fig. 6d). Moreover, GFAP staining
highlighted intense glial activation and aberrant glial proliferation
at the retinal surface of rPGF-1-treated diabetic eyes as compared
to untreated GK rats (Fig. 6e). As glial proliferation contributes to
the early steps of peri-retinal membrane formation [46], PGF could
intervene in the induction of pre-retinal gliosis observed in PDR.
To check this hypothesis, we localized PGF by immuno-detection
in two membranes excised from eyes with PDR.
Figure 4. Angiogenic response on retinal vascular cells. (a-d) Confocal microscopy of vascular abnormalities within the neural
retina, one month after pVAX2-rPGF-1 ET. Confocal microscopy of flat-mounted neuroretinas from eyes in which rPGF-1 was over-expressed
shows lectin-positive blood vessels and cells at different depth levels, from the superficial (1) to the deep vascular plexus (4). Scale bars = 50 mm. (a, b)
The abnormalities noticed in vivo on SLO angiograms from two eyes were found on retinal flat-mounts by comparison of the vascular architectures.
(c, d) For illustration, retinal flat-mounts have been turned into grey-scale pictures. Red asterisks indicate the presence of infiltrating cells around
vascular abnormalization. (e) Optic microscopy of vascular abnormalities within flat-mounted retinas, two months after ET. Vascular
abnormalities (e1), sprouts (e2) and microaneurysmal-like structures (e3) were observed between the inner and the middle vascular beds. (f) Q PCR
analysis of VEGF, IL-1beta, TNF-alpha and IL-6, two months after ET, in retina of control (in white, n = 3 in duplicate) and pVAX2-rPGF-1 ET
treated (in black, n = 5 in duplicate) retina from BN rats. ***, p,0.005 versus wildtype mRNA expression. Data represent mean 6 SEM.
doi:10.1371/journal.pone.0017462.g004
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Immunohistochemical analysis of epiretinal membranes
from diabetic patients
PGF was detected in peripheral cells of the pre-retinal
membranes (Fig. 8a arrow) and in cells forming tubes, resembling
vascular cells (Fig. 8a magnified). GFAP and von Willebrand
factor co-staining demonstrated the fibro-vascular nature of the
membranes (Fig. 8b–e). PGF was localized in some GFAP-positive
(Fig. 8b–c) and in some vascular ECs (Fig. 8d–e).
Discussion
The pro angiogenic effect of VEGFwas demonstrated by the acute
exposure of rat and monkey retinas, inducing an intense and quick
pre retinal neovascularization [10]. Such pro angiogenic effects were
not reported after acute exposure of the retina to PGF. Indeed,
previous studies have shown that an acute administration of PGF in
the mouse [39] or in the rat vitreous [19] had no effect on retinal
vessels, suggesting that PGF had no clear pro angiogenic activity.
However, in pathologic conditions, abnormalities are observed after
years of sustained cytokinic and growth factors local deregulation.
This is the reason why our model is based on a sustained secretion of
PGF in the vitreous of normal or diabetic rat eyes.
The progressive retinal vessels abnormalization was followed up
in vivo by FA. The release of rPGF-1 in ocular fluids had no effect
after a week, but then chronologically induced the dilation and
increased tortuosity of retinal vessels, the formation of microan-
eurysms and vascular sprouts together with increased vessel
permeability. Nevertheless, no real pre-retinal neovessels have
been observed over the experimental period. PGF effect therefore
differs from VEGF which solely induces vitreous neovasculariza-
Figure 5. Effect of PGF over expression on retinal histology and on RPE cells. (a–b) Histological sections of retinas from eyes
embedded in historesin and stained by Toluidine blue, three months after saline (a1, b1) and pVAX2-rPGF-1 ET (a2–a4, b2–b4). (a1)
Normal histological section of the retina after pVAX2 ET. ch, choroid; gcl, ganglion cell layer; inl, inner nuclear layer; onl, outer nuclear layer; rpe,
retinal pigmented epithelium; Sc, Sclera. Scale bar (a1–4) = 100 mm. (a2) Histological section of pVAX2-rPGF-1 ET-treated retinas, showing vascular
retinal abnormalities in the inner part of the peripheral retina. (a3) Sections showing retinal detachment (star) associated with pre-retinal proliferation
(arrow) and edema at the ONL level (magnified in b3 inset). (a4) Sections showing retinal detachment (star) associated with RPE barrier breakdown.
(b1) Section at high magnification showing normal RPE cells after PBS ET. Scale bar (a1–4) = 10 mm. (b2–b4) Magnified RPE cells of the retinal sections
(a2–a4) demonstrating morphological changes of RPE cells which appears swollen, and dilation of the chorio-capillaries (b2, b4 black arrowheads).
Background has been subtracted in all pictures. (c) Sustained blood-retinal barrier breakdown induced by rPGF-1 over expression. Tight
junctions were observed by occludin immuno-histochemistry on whole flat-mounted RPE cells. (c1–3) Normal tight junction-associated occludin was
observed in PBS-ET treated eyes. Scale bar = 20 mm. (c2–4) Two months after pVAX2-rPGF-1 ET, junctions remained opened between some RPE cells
(white arrows). At this opened junction level, infiltrating cells (stars) are also detected by the DAPI staining and recognized by the small size of their
nuclei as compared to those of RPE cells.
doi:10.1371/journal.pone.0017462.g005
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tion. Interestingly, recent observations made in tumor vasculari-
zation pointed out that abrogation of PGF by different means did
not influence vascular density but reduced significantly abnorma-
lization of the vessels, such as tortuosity and disorganization [47].
Our results are in agreement with this observation, showing that
PGF may be involved in the first phase of diabetic retinopathy
when only microaneurysms are present. In GK rats, a model of
type 2 diabetes, we showed that PGF progressively increased in the
retina from 2 to 5 months and remained at high level for at least
12 months. Together with this endogenous PGF over-expression,
we have observed vascular abnormalities, similar to those obtained
in non diabetic rats by PGF over-expression. However, contrarily
to humans, no pre-retinal neovascularization and no ischemic area
are observed in this model, even at late stages. Interestingly, the
Figure 6. PGF expression in diabetic retina. (a–b) Comparison of PGF staining in non diabetic (a) and diabetic (b) retinas. (a) Sections
of eyes from adult control non diabetic rat showed co-expression of PGF and GFAP in glial Muller cells from the gcl (arrowheads) to the inl, and PGF
expression in glial Mu¨ller cells which are not immuno-reactive for GFAP (white star). Scale bar = 50 mm. (b) A similar pattern was observed on retinal
sections of eyes from three-month-old diabetic rats, with a strong immuno-reactivity for PGF at the gcl level. (c) PGF detection by Western-blot
in diabetic and non-diabetic retinas, from 1, 2, 5 and 12 month-old rats. For each lane in which 40 mg of proteins were deposited, the blood
sugar level of the represented rats is indicated between parentheses. (d–e) Immunostaining for PGF and GFAP in sections from pVAX2-
rPGF-1 ET- treated diabetic rat eyes, one month after ET. Sections show PGF-expressing infiltrating cells in the sub retinal space (d, arrows)
and confirmed PGF expression by RMG cells (d, arrowheads). GFAP staining showed gliosis induced by RMG cells (d, e). ch, choroid; gcl, ganglion cell
layer; inl, inner nuclear layer; ipl, inner plexiform layer; onl, outer nuclear layer; rpe, retinal pigmented epithelium; Scale bar = 100 mm.
doi:10.1371/journal.pone.0017462.g006
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over-expression of PGF in diabetic rats did not enhance the
phenotype of diabetic retinopathy, even if it may have increased
the cell infiltration. Other factors, among which the over
expression of VEGF, are probably required to induce pre-retinal
neo-vessels.
Taken together, these observations suggest that PGF may
contribute to the early vascular abnormalization taking place in
the early phases of DR. Under physiological conditions, the adult
retinal vascular cells mostly express Flt-1 [48], and we have shown
that in normal retina RMG cells express PGF, suggesting that PGF
could intervene in the neurovascular control. PGF over-expressed
in the neuroretina binds to its specific receptor, Flt-1, and
contributes to alter the vessels wall leading to leakage, vessel
dilatation and aneurysmal formations. Consistent with our finding,
Figure 7. Analysis of flat-mounted diabetic retinas labeled with FITC-conjugated lectin from Bandeira simplicifolia, one month after
ET. (a) Quantitative analysis of the retinal vasculature from control and PGF ET-treated diabetic rat eyes. (b) Microscopy of flat-
mounted control (b1, b3) and PGF ET-treated (b2, b4) diabetic retinas. (b1–b2) Optic microscopy on mosaics made with microscopic images
at low magnification (x4) showing no evident difference of the retinal vascularization between control (b1) and pVAX-2-rPGF-1 ET-treated eyes (b2),
except a weak retinal venous dilation in treated retinas (between arrowheads). (b3, b4) Confocal microscopy showing lectin-labeled cell infiltration
(arrow) and micro-aneurysmal-like structures observed in both group (insets).
doi:10.1371/journal.pone.0017462.g007
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a recent study reported that VEGF and PGF ablate pericytes from
the retinal vasculature through the ERK signaling pathway
mediated by Flt-1, confirming its role in the breakdown of the
inner blood retinal barrier [49]. The PGF-induced effects on
retinal vasculature could result from a direct Flt-1 activation, but
also from the PGF-induced VEGF displacement from Flt-1 and
sFlt-1 toward Flk-1, which is over-expressed in pathological
conditions. Moreover, hetero-dimerization of PGF with VEGF
could exert mitogenic effects on endothelial cells by activating
inter- and intra-molecular interactions between both VEGF
receptors [23]. In addition, PGF indirectly stimulates angiogenesis
by recruiting inflammatory cells, and so, by amplifying VEGF and
pro-inflammatory cytokine production [32].
Surprisingly, in our model, IL-1beta and TNF-alpha, which are
among the more pro angiogenic inflammatory cytokines, were
down regulated in the retina submitted to sustained PGF exposure.
Indeed, PGF has been shown to trigger production of pro-
inflammatory cytokines as TNF-alpha and IL-1beta in monocytes
from patients with single cell disease [50], as well as TNF-alpha
and IL-6 in the synovial tissue from patient with rheumatoid
inflammation [51]. However, it has also been demonstrated that
PGF modulates differentiation and maturation of dendritic cells in
response to LPS, inhibiting NF-kappaB activity, and so inhibiting
TNF-alpha production [52]. These studies suggest that PGF
effects depend on target cells and on their environment. Our
model showed that, after two months of production, rPGF-1
maintained VEGF expression promotion, but significantly down-
regulated IL-1beta and TNF-alpha expression in retinal cells. This
observation suggests that PGF may influence the cytokinic retinal
micro-environment and may modulate the function of retinal
inflammatory cells, as microglia. As IL-1beta and TNF-alpha are
among the most pro-angiogenic inflammatory cytokines, their
down-regulation may explain in part why no real vitreoretinal
neovascularization occurred.
On the other hand, a significant increase in IL-6 resulted from
PGF over expression. The exact significance of this increase
remains to be determined, as IL-6 can have pro or anti
inflammatory effects. Withal, a recent clinical study showed that
Figure 8. Immunostaining for PGF (a–e), GFAP (b, c) and von Willebrand factor (d, e) in membrane excised surgically from a 60-
year-old woman with proliferative diabetic retinopathy. (a) PGF was immuno-detected on the epi-retinal membrane. It was localized in GFAP
(b–c, arrows) and von Willebrand factor (vW) (d–e, arrows) immuno-positive cells. Red stars indicate cells expression only GFAP (c) or vW (d), and
green stars show non-endothelial cells expressing PGF.
doi:10.1371/journal.pone.0017462.g008
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ten weeks after intravitreal injection of bevacizumab (AvastinH,
Genentech), a monoclonal antibody targeting VEGF, recurrence
of edema occurred with low VEGF levels and high IL-6 levels in
the aqueous humor [53], suggesting that PGF-induced IL-6
production may contribute to vascular permeability. The permea-
bilizing effect of PGF was also observed at the outer retinal barrier
level, where disrupted occludin staining was observed at the tight-
junctions together with changes in the morphology of RPE cells,
suggesting alteration of this barrier, as previously described after
acute PGF injection in the rat [19].
In the early phases of DR, alterations of retinal capillaries and
focal aneurismal deformations progressively develop, very similar
to what was observed in retina exposed chronically to PGF or in
retina from GK rats. We therefore hypothesize that PGF could act
in synergy with VEGF in the early phases of diabetic retinopathy.
As dosing PGF/VEGF in the vitreous of patients at the early
phases of the disease is not possible, we have looked at PGF
expression in fibro-vascular membranes extracted from vitrectomy
in patients with PDR. PGF was found not only in ECs but also in
glial cells. We have also observed that PGF was expressed in glial
cells in the normal rat retina and that PGF over-expression
induced an intense glial activation. PGF could therefore also
intervene in glial alterations observed in DR.
The implications PGF and its receptor has recently been
demonstrated in several pathological conditions, particularly in
oncology [32], leading to the development of new therapeutic
molecules: TB-403 (Thrombogenics), a monoclonal anti-PGF
antibody [54], and aflibercept (VEGF TrapH, Regeneron
Pharmaceuticals/Bayer). This soluble VEGF receptor fusion
protein designed to bind all forms of VEGF along with PGF, was
formulated for intravitreal injections (VEGF Trap-Eye). These new
drugs could have a therapeutic benefit for DR, and notably for
diabetic macular edema. Positive results of a phase II study in
patients with diabetic macular edema treated with VEGF Trap Eye
came recently and showed a significant improvement in visual
acuity over 24 weeks compared to macular laser therapy,
demonstrating that blocking both Flt-1 ligands is efficient to limit
macular edema formation [55]. Nevertheless, others GFs implied in
DR, FGF-2 and EGF, may also be able to indirectly induce Flt-1
expression in ECs in a combinatorial fashion [56]. Thus, it would
also be of interest to target Flt-1.
In summary, diabetic retinal changes might result from
synergistic actions of several GFs. Our results suggest that PGF-1
could participate to vessel abnormalization observed in the early
stages of DR. In patients, the vascular changes may result from the
balance between VEGF/PGF and sFLT-1 in the ocular media at
the different stages of the disease progression. Further studies are
therefore required to analyze how the expression the VEGF
receptors and their ligands are modulated during diabetic
retinopathy.
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